- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05126875
Re-TREAT: Re-irradiation for Relapsed Brain Metastases (RE-TREAT)
Re-TREAT: A Phase 2 Study of Stereotactic Re-irradiation of Relapsed Brain Metastases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background It is estimated that 10-20 % of patients with cancer develop brain metastases (BM) and the number is increasing due to prolonged patient survival as a result of improvements in surgery and systemic treatment. With few exceptions however, chemotherapy is not effective in treating disease within the central nervous system and therefore BM are often treated as a separate compartment independently from the rest of the disease throughout the body. Treatment modalities include surgical resection, stereotactic radiosurgery (SRS) and whole brain irradiation (WBI) or a combination.
SRS is a technique where a high dose of radiation is delivered through multiple fields, often as rotational intensity modulated radiation therapy (IMRT), where the beam is aimed at the tumor from everchanging angles, in order to minimize the dose to the surrounding tissue. In contrast to other radiation modalities, where a margin is added to the target in order to eradicate tumor cells that are not visible on imaging, SRS employs very small margins because brain metastases tend to be localized with sharp boundaries to surrounding tissue. The relative low dose absorbed by the surrounding tissue allows for delivery of the whole radiation dose to the tumor in one to three treatment sessions ('fractions'), as opposed to conventionally fractionated radiotherapy which is delivered in multiple fractions for the protection of surrounding healthy tissue.
As a whole, SRS results in high rates of local tumor control (65-90%) and low rates of toxicity (10-15%), which is usually mild. The most significant adverse event following SRS is radionecrosis, which is estimated to occur in 5-25% of patients. This is a condition which is poorly defined but is commonly used to describe a situation where the contrast enhancing area in the irradiated volume increases, often accompanied by increasing edema in the surrounding tissue. The condition may or may not cause symptoms. In cases of symptomatic, progressive radionecrosis, oral corticosteroids such as prednisolone may be needed for longer periods of time. Differentiation between relapsed metastasis and radionecrosis is notoriously difficult and represents one of the major diagnostic challenges in all of neuro-oncology. Advanced imaging techniques such as dynamic MRI (e.g. perfusion weighted images) or PET (positron emission tomography) have been used to aid in differentiation in experimental studies, but this currently remains an area of research. The development of the brain lesion over time and use of close follow-up using MRI will most often aid in interpretation of the images by the multidisciplinary team conference consisting of a radiologist, a radiation oncologist and a neurosurgeon.
There is no standard treatment in case of local tumor relapse following SRS. Patients who have not previously received WBI may be offered this, but the possible detrimental effects on neurocognition and quality of life are well documented4 and many clinicians as well as patients prefer to avoid this for as long as possible. Few patients in this category are recommended surgical resection.
Salvage SRS (repeated SRS to the same area at time of relapse) is commonly practiced at some institutions, Rigshospitalet being one of them, but the evidence to support routine use is sparse. The treatment has been evaluated only in retrospective studies. These have found high rates of local control (70-90%), but as adverse events and side effects cannot be evaluated from retrospective studies without risk of critical bias, the safety of this treatment remains to be established.
Aim of the study The Re-TREAT study is a prospective clinical, phase 2, interventional, single-arm, multicenter trial with patients with local relapse of one or more brain metastases. In the trial, they are treated with salvage SRS. The aim is to evaluate the efficacy and toxicity of salvage SRS. The primary outcome is local control of the relapsed tumor and the secondary endpoints include toxicity as evaluated by the investigator and quality of life measured as a patient reported outcome. As an exploratory endpoint, the value of advanced MRI and PET-imaging as a biomarker for prediction of response to treatment or toxicity will be studied.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Søren Møller, MD, PhD
- Phone Number: +45 35451693
- Email: soeren.moeller.01@regionh.dk
Study Contact Backup
- Name: Gitte F Persson, MD, PhD
- Phone Number: +45 38689299
- Email: gitte.persson@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- Rigshospitalet, University of Copenhagen
-
Contact:
- Søren Møller, MD
- Phone Number: +4535451693
- Email: soeren.moeller.01@regionh.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Brain metastases of solid tumor (carcinoma of unknown origin may be included but histological verification in case of BM alone is required)
- Progression of previously treated lesion as decided by the multidisciplinary team conference
- Previous single fraction SRS in area in question and dose plans must be available electronically
- Previous single fraction SRS given > 3 months previously
- ECOG (Eastern Cooperative Oncology Group) performance status ≤2
- Life expectancy >3 months
- Signed written consent.
- Patients may have more than one recurring lesion and may also have new, untreated metastases which may be treated with standard SRS (up to a total of 4 metastases in accordance with Danish national guidelines).
Exclusion Criteria:
- Two previous courses of radiotherapy for the same metastasis (e.g. SRS and WBRT)
- Target lesions located in- or in proximity to eloquent brain areas that require reduction of radiotherapy dose
- Target lesion gross tumor volume (GTV) for radiotherapy greater than 14,1 cm3 (equivalent to a sphere with a diameter of 3 cm)
- Current or planned concomitant medical treatment that is likely to be active against brain metastases (e.g. tyrosine kinase inhibitors for EGFR-positive (epidermal growth factor receptor) non-small cell lung cancer) or that may influence interpretation of images (e.g. bevacizumab, a monoclonal antibody directed towards VEGF (vascular endothelial growth factor)) in the opinion of the investigators
- Contraindication to magnetic resonance imaging using Gadolinium contrast enhancement (e.g. pacemaker, metallic implant or impaired renal function)
- Rapid extracranial disease progression that in the opinion of the investigators confer a high risk of drop out from the study without evaluation scan at 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
Treatment with stereotactic radiosurgery
|
Repeated stereotactic radiosurgery to recurring brain metastases
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from progression of treated metastasis
Time Frame: 3 months post treatment
|
Freedom from progression of lesion size defined as stable or decreasing unidimensional measurement (longest diameter) on T1-weighted contrast enhanced magnetic resonance imaging (MRI)
|
3 months post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 12 months
|
Adverse events graded using National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Adverse Events (AE) version 5.0
|
12 months
|
Overall response
Time Frame: 3 months
|
Overall radiographic response of all treated lesions
|
3 months
|
Neurological status
Time Frame: 6 months
|
Neurological status assessed by NANO (neurologic assessment in neuro-oncology) scale
|
6 months
|
Time to intracranial relapse
Time Frame: From date of treatment until the day of radiologically documented relapse in the brain assessed up to 12 months
|
Time to recurrence of treated lesion or occurrence of new lesion(s)
|
From date of treatment until the day of radiologically documented relapse in the brain assessed up to 12 months
|
Overall survival
Time Frame: From date of treatment until date of death from any cause assessed up to 12 months
|
Overall survival from entry into study
|
From date of treatment until date of death from any cause assessed up to 12 months
|
Patient reported outcomes
Time Frame: 6 months
|
Health related quality of life measured by the FACT-Br (Functional Assessment of Cancer Therapy - Brain) questionnaire
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positron emission tomography using fluoro-ethyl tyrosine (FET) tracer before and after treatment
Time Frame: 3 months
|
Exploratory endpoint.
The measured change in biological tumor volume (BTV) and Tmax/brain (maximal tumor activity) as compared to baseline values.
|
3 months
|
Dynamic MRI using DCE (dynamic contrast enhancement) perfusion measurement before and after treatment
Time Frame: 3 months
|
Exploratory endpoint.
The measured change in tumor blood volume measurement, tumor perfusion and tumor permability (Ki) as compared to baseline values.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Søren Møller, MD, PhD, Rigshospitalet, Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RE-TREAT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Repeated stereotactic radiosurgery
-
Accuray IncorporatedUniversity of PittsburghUnknownNon-small Cell Lung CancerUnited States, China
-
University of Alabama at BirminghamCompletedBrain MetastasesUnited States
-
University Hospital OstravaInstitute for Clinical and Experimental Medicine; Hospital PodlesiRecruitingVentricular TachycardiaCzechia
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm in the BrainUnited States, Canada
-
Barretos Cancer HospitalWithdrawn
-
University of ChicagoRecruiting
-
Washington University School of MedicineTerminated
-
Stanford UniversityCompletedBrain (Nervous System) Cancers | Spinal Cord CancerUnited States
-
Tel-Aviv Sourasky Medical CenterUnknown
-
University of LouisvilleJames Graham Brown Cancer CenterTerminatedVertebral MetastasisUnited States